20/20 Biolabs Inc (NASDAQ:AIDX) Shares Shorted: Short Interest Up 405.8% in October

Posted by Linda Flegge on Nov 12th, 2026

20/20 Biolabs Inc (NASDAQ:AIDX – Get Free Report) saw a large increase in short interest during the month of October. As of October 30th, there was short interest totaling 57,001 shares, an increase of 405.8% from the October 15th total of 11,270 shares. Based on an average daily volume of 160,271 shares, the short-interest ratio is presently 0.4 days. Approximately 0.6% of the shares of the stock are sold short.

20/20 Biolabs Price Performance

Shares of NASDAQ:AIDX traded down $0.02 during trading on Thursday, reaching $0.20. 164,608 shares of the stock were exchanged, compared to its average volume of 397,823. 20/20 Biolabs has a 1-year low of $0.18 and a 1-year high of $50.00. The firm has a market cap of $2.67 million and a price-to-earnings ratio of -0.37. The stock has a fifty day moving average of $0.37 and a two-hundred day moving average of $0.95.

20/20 Biolabs (NASDAQ:AIDX – Get Free Report) last announced its quarterly earnings results on Friday, August 14th. The company reported ($0.26) earnings per share (EPS) for the quarter. The company had revenue of $0.73 million during the quarter.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “sell (e)” rating on shares of 20/20 Biolabs in a research report on Friday, October 30th. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $5.00.

Check Out Our Latest Stock Report on AIDX

20/20 Biolabs Company Profile

(Get Free Report)

We develop and commercialize AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases. We offer two families of lab tests, both under our OneTest brand: (i) OneTest for Cancer, a multi-cancer early detection, or MCED, blood test which has been our primary commercial focus and source of revenues since we wound down our COVID-19 testing business, and (ii) OneTest for Longevity, which measures inflammatory biomarkers, that we expect to launch in the first half of 2026.